

Lanreotide improves survival with enteropancreatic tumors

21 July 2014



Image courtesy of Blausen Medical

"Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic [neuroendocrine tumors](#) of grade 1 or 2 (Ki67

The study was funded by Ipsen, the manufacturer of lanreotide.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2014 [HealthDay](#). All rights reserved.

(HealthDay)—Lanreotide significantly improves survival among patients with metastatic enteropancreatic neuroendocrine tumors (grade 1 or 2), according to a study published in the July 17 issue of the *New England Journal of Medicine*.

Martyn E. Caplin, D.M., from Royal Free Hospital in London, and colleagues conducted a multinational study of [patients](#) with advanced, well-differentiated or moderately-differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors (grade 1 or 2 that originated in the pancreas, midgut, or hindgut, or were of unknown origin) and documented disease-progression status. Participants were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks.

The researchers found that, compared to placebo, lanreotide was associated with significantly prolonged progression-free [survival](#) (P placebo group). In predefined subgroups, the therapeutic effect was generally consistent with that found in the overall population. Groups were similar in quality of life and overall survival. Diarrhea was the most common treatment-related adverse event (26 percent of the lanreotide group versus 9 percent of the [placebo group](#)).

APA citation: Lanreotide improves survival with enteropancreatic tumors (2014, July 21) retrieved 17 November 2019 from <https://medicalxpress.com/news/2014-07-lanreotide-survival-enteropancreatic-tumors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.